Charles T. Van Buren, M.D.

Professor of Surgery and Director of the
Division, Medical Director: LifeGift, Renal Transplantation-Memorial Hermann Hospital, St. Luke's Episcopal Hospital.

Download CV (PDF)

Biography

Dr. Charles Van Buren began his career in nutrition research, doing his residency in general surgery at the Peter Bent Brigham Hospital, where he worked with the physicians who did the initial work in transplantation between identical twins, including Nobel Prize winner Dr. Joseph Murray. He came to the Division of Immunology and Organ Transplantation in 1977 to expand his experience in organ transplantation and add a new dimension to the Division's research efforts, nutritional immunology. As a surgeon, Dr. Van Buren performed the first liver transplant in Houston in 1985. Dr. Van Buren currently serves as Professor of Surgery, Director of the Division, and Medical Director of LifeGift.

Selected publications

Benavides CA, Csapo Z, Timmins K, Holley L, Katz SM, Van Buren CT, Kahan BD. Fibromuscular dysplasia recurrence after kidney transplantation: case report. Clin Nephrol. 2006 Jul;66(1):67-70.

Csapo Z, Knight RJ, Podder H, Kerman RH, Schoenberg L, Katz SM, Van Buren CT, Kahan BD. Long-term outcomes of single paediatric vs. ideal adult renal allograft transplants in adult recipients. Clin Transplant. 2006 Jul-Aug;20(4):423-6.

Knight RJ, Kerman RH, Zela S, Podbielski J, Podder H, Van Buren CT, Katz S, Kahan BD. Pancreas transplantation utilizing thymoglobulin, sirolimus, and cyclosporine. Transplantation. 2006 Apr 27;81(8):1101-5.

Knight RJ, Kerman RH, McKissick E, Lawless A, Podder H, Katz S, Van Buren CT, Kahan BD. A pilot study of immunosuppression minimization after pancreas-kidney transplantation utilizing thymoglobulin induction and sirolimus maintenance therapy. Transplant Proc. 2005 Oct;37(8):3538-41.

Kahan BD, Yakupoglu YK, Schoenberg L, Knight RJ, Katz SM, Lai D, Van Buren CT. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation. 2005 Sep 27;80(6):749-58.

Knight RJ, Kerman RH, Podder H, Katz SM, Van Buren CT, Kahan BD. Graft survival and immune regulation of pancreas allograft recipients induced with thymoglobulin, sirolimus, and cyclosporine. Transplant Proc. 2005 Mar;37(2):1280-2.

Benavides C, Mahmoud KH, Knight R, Barcenas C, Kahan BD, Van Buren CT. Rabbit antithymocyte globulin: a postoperative risk factor for sirolimus-treated renal transplant patients? Transplant Proc. 2005 Mar;37(2):822-6.

Csapo Z, Knight RJ, Podder H, Kerman RH, Schoenberg L, Katz SM, Van Buren CT, Kahan BD. Transplantation of single pediatric kidneys into adult recipients. Transplant Proc. 2005 Mar;37(2):697-8.

Shafer TJ, Ehrle RN, Davis KD, Durand RE, Holtzman SM, Van Buren CT, Crafts NJ, Decker PJ. Increasing organ recovery from level I trauma centers: the in-house coordinator intervention. Prog Transplant. 2004 Sep;14(3):250-63.

Shafer TJ, Van Buren CT, Andrews CA. Program development and routine notification in a large, independent OPO: a 12-year review. J Transpl Coord. 1999 Mar;9(1):40-9.

Kahan BD, Wong RL, Carter C, Katz SH, Von Fellenberg J, Van Buren CT, Appel-Dingemanse S. A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients. Transplantation. 1999 Oct 27;68(8):1100-6.

Kerman RH, Susskind B, Buyse I, Pryzbylowski P, Ruth J, Warnell S, Gruber SA, Katz S, Van Buren CT, Kahan BD. Flow cytometry-detected IgG is not a contraindication to renal transplantation: IgM may be beneficial to outcome. Transplantation. 1999 Dec 27;68(12):1855-8.

Kahan BD, Napoli KL, Kelly PA, Podbielski J, Hussein I, Urbauer DL, Katz SH, Van Buren CT. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin Transplant. 2000 Apr;14(2):97-109.

Kahan BD, Welsh M, Urbauer DL, Mosheim MB, Beusterien KM, Wood MR, Schoenberg LP, Dicesare J, Katz SM, Van Buren CT. Low intraindividual variability of cyclosporin A exposure reduces chronic rejection incidence and health care costs. J Am Soc Nephrol. 2000 Jun;11(6):1122-31.

Langer RM, Van Buren CT, Katz SM, Kahan BD. De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine a sirolimus combination. Transplant Proc. 2001 Nov-Dec;33(7-8):3236-7.

El-Sabrout RA, Radovancevic B, Ankoma-Sey V, Van Buren CT. Guillain-Barre syndrome after solid organ transplantation. Transplantation. 2001 May 15;71(9):1311-6.

Kahan BD, Napoli KL, Podbielski J, Hussein I, Katz SH, Van Buren CT. Therapeutic drug monitoring of sirolimus for optimal renal transplant outcomes. Transplant Proc. 2001 Feb-Mar;33(1-2):1278.

Podder H, Podbielski J, Hussein I, Katz SM, Van Buren CT, Kahan BD. Impact of sirolimus on renal transplant outcomes in African Americans. Transplant Proc. 2001 Feb-Mar;33(1-2):1226.

Kerman RH, Katz SM, Van Buren CT, Ruth J, McKissick E, Rasmussen S, Kahan BD. Posttransplant immune monitoring of anti-HLA antibody. Transplant Proc. 2001 Feb-Mar;33(1-2):402.

Kerman RH, Katz SM, Van Buren CT, Garcia C, Kahan BD. Addition of rapamycin to cyclosporine-prednisone based immunosuppression reduces the clinical risk of pretransplant anti-HLA antibody. Transplant Proc. 2001 Feb-Mar;33(1-2):401.

Langer RM, Van Buren CT, Katz SM, Kahan BD. De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine-sirolimus combination. Transplantation. 2002 Mar 15;73(5):756-76